Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.

Immunogenicity of therapeutic recombinant immunotoxins. Immunol Rev (2016) 0.88

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity. Oncotarget (2016) 0.77

Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4(+) T Cells. Front Immunol (2017) 0.75

HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost. PLoS One (2016) 0.75

Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins. Biomedicines (2017) 0.75

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62

Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98

HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature (2012) 3.83

Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 3.25

Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics (2010) 2.53

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis (2004) 2.01

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol (2012) 1.75

Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis (2003) 1.33

HLA-A, -B, -DRB1, -DQA1, and -DQB1 polymorphism in Thais. Hum Immunol (1997) 1.03

HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses. PLoS One (2012) 0.92

A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences. Vaccine (2000) 0.91

CD4+ T-lymphocyte lines developed from HIV-1-seropositive patients recognize different epitopes within the V3 loop. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.82

Shaping T cell - B cell collaboration in the response to human immunodeficiency virus type 1 envelope glycoprotein gp120 by peptide priming. PLoS One (2013) 0.80

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. EBioMedicine (2014) 0.92